Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Henlius Sells Southeast Asia Rights for PD-1 to Kalbe Genexine in $692 Million Deal

publication date: Sep 24, 2019

Shanghai Henlius Biotech announced a $692 million partnership with Kalbe Genexine Biologics for Southeast Asian rights to Henlius' PD-1 checkpoint inhibitor. Kalbe Genexine is a JV formed by Kalbe Farma of Indonesia and Genexine of South Korea. Henlius, the biologics arm of Fosun Pharma, will receive $10 million upfront, $22 million in regulatory milestones, $650 million in commercial milestones and $10 million for combination trials. Last week, Henlius completed a $410 million IPO on the Hong Kong Exchange. More details....

Stock Symbols: (HK: 2696) (SHA: 600196; HK: 2196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.